SanBio Company Limited (4592.T) JPX

Currency In JPY

SanBio Company Limited

Address

St. Luke Tower

Tokyo, 104-0044

Japan

Phone

81 3 6264 3481

Website

https://www.sanbio.jp

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

April 08, 2015

Key Executives

Name	Title	Pay	Year Born
Keita Mori	Co-Founder, President, Executive Officer, Chief Executive Officer & Representative Director	0	1967
Kazumi Sawaguchi	Corporate Officer and Head of Japan Regulatory Affairs & Quality Compliance Japan	0	N/A
Dai Chida	Senior Scientific Advisor	0	N/A
Naoki Tsukahara	Senior Corporate Officer	0	N/A
Shinya Hirata	Corporate Officer & Head of Research and Development	0	N/A
Soyoku Nobeyama	Corporate Officer, Head of Japan Regulatory Affairs & Quality Compliance Japan	0	N/A
Tetsuya Isono	Corporate Officer & Head of Production	0	N/A
Toru Kawanishi	Co-Founder & Executive Chairman	0	1967
Yoshihiro Kakutani	Corporate Officer of Management Administration	0	N/A
Munetaka Nobeyama	Executive Officer, Head of Reliability Assurance & Regulatory Affairs Division	0	N/A

Description

SanBio Company Limited is dedicated to the creation, production, and sale of regenerative cell therapies, primarily concentrated on disorders of the central nervous system. A central component of their portfolio is SB623, a treatment that has completed Phase 2 clinical trials in both the United States and Japan for traumatic brain injury. Beyond this, their comprehensive research pipeline explores the broader potential of SB623 for conditions such as ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease. The company's development efforts also encompass other innovative treatments: SB618 for peripheral nerve damage, SB308 for muscular dystrophy, MSC1 for cancer, and MSC2 for inflammatory diseases and optic neuritis. Founded in 2001, SanBio maintains its corporate headquarters in Tokyo, Japan.